Trial no.:
|
PACTR201709002522352 |
Date of Approval:
|
17/08/2017 |
Trial Status:
|
Registered in accordance with WHO and ICMJE standards |
|
TRIAL DESCRIPTION |
Public title
|
Botulinum toxin augmented surgery vs conventional surgery in the management of large angle infantile esotropia |
Official scientific title |
Botulinum toxin augmented surgery versus conventional surgery in the management of large angle infantile esotropia |
Brief summary describing the background
and objectives of the trial
|
Infantile esotropia is defined as the onset of constant convergent squint in children less than 6 months of age. Infantile esotropia is mainly treated surgically using either bilateral medial rectus muscle recessions or unilateral medial rectus muscle recession and lateral rectus muscle resection with the main goal being to align the eyes so that single binocular vision may develop. For infants with very large angles of esotropia (>60 prism diopters [PD]), surgery on 2 muscles alone may not be adequate. Approaches to these patients have included large bilateral medial rectus muscle recessions, smaller bilateral medial rectus muscle recessions combined with resections of 1 or both lateral rectus muscles or botulinum toxin augmented bimedial recession.
Botulinum toxin augmentation of medial rectus muscle recession was reported in three previous studies. Lueder et al evaluated the long-term outcomes in patients with infantile esotropia. The results were good, with a 74% success rate(8). Based on historical comparisons, this technique appears equally as effective as 3- or 4-muscle surgery and more effective than large bilateral medial rectus recessions alone.
Ideally, a prospective randomized study should be performed to more definitively determine which of these approaches is best. |
Type of trial |
RCT |
Acronym (If the trial has an acronym then please provide) |
|
Disease(s) or condition(s) being studied |
infantile esotropia,Neonatal Diseases,Surgery |
Sub-Disease(s) or condition(s) being studied |
|
Purpose of the trial |
Treatment: Surgery |
Anticipated trial start date |
01/09/2017 |
Actual trial start date |
|
Anticipated date of last follow up |
31/08/2019 |
Actual Last follow-up date |
|
Anticipated target sample size (number of participants) |
46 |
Actual target sample size (number of participants) |
|
Recruitment status |
Not yet recruiting |
Publication URL |
|
|